Notably, KRAS, BRAF, ERBB2, PIK3CA, RET, ROS1, ALK, and NRTK1/2/3 have been proposed as prognostic markers, making substantial contributions to genotype-directed therapies for advanced lung cancer. This evidence concerns the gene ROS1 and lung carcinoma.